Wednesday, December 21, 2011

Ariad Pharmaceuticals Still Might Have Upside - Investorplace.com

callahamirykaan1884.blogspot.com


Ariad Pharmaceuticals Still Might Have Upside

Investorplace.com


It appears they're banking heavily on approval of Ariad's leukemia treatment ponatinib in 2013. The drug garnered rave reviews at the recent American Society of Hematology meeting in San Diego, with impressive results treating study patients with ...



and more »

No comments:

Post a Comment